[Chronic hepatitis B: which patients should be treated and how?].
Asselah
Tarik
T
Hépatologie, INSERM U481, Hôpital Beaujon, Clichy, France.
Ripault
Marie-Pierre
MP
Marcellin
Patrick
P
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D063065:Organophosphonates / Q000627:therapeutic use; D010347:Patient Care Planning; D018579:Patient Selection; D011092:Polyethylene Glycols; D011379:Prognosis; D011994:Recombinant Proteins
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D063065:Organophosphonates; D011994:Recombinant Proteins; D019259:Lamivudine; D011092:Polyethylene Glycols; C053001:adefovir; C417083:peginterferon alfa-2b; D000225:Adenine